Labiotech.eu

crispr therapeutics vertex beta thalassemia

News and Trends 19 Nov 2019

CRISPR Cell Therapy Shows Early Promise for Treating Blood Disorders

CRISPR Therapeutics and its US partner Vertex Pharmaceuticals have released the first clinical results for a cell therapy made using the gene editing tool CRISPR/Cas9 in patients with genetic blood disorders. The interim results concern two patients enrolled in different phase I/II clinical trials testing the same therapy in two blood disorders: transfusion-dependent beta-thalassemia and […]

November 19, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 19 Nov 2019

US-French Deal to Tailor Ultrasound Therapy to Brain Cancer Patients

The French company CarThera has teamed up with the US firm Kiyatec to study the effects on individual patients of an ultrasound therapy to deliver brain cancer drugs to the brain. Under the agreement, Kiyatec will test the effects of chemotherapy on cells taken from CarThera’s ongoing phase I/II trial in patients with brain cancer. […]

November 19, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 18 Nov 2019

Update: Single-Shot Vaccine for Chikungunya Lasts for a Year in Phase I

Update (18/11/2019): French biotech Valneva has revealed additional phase I results concerning its experimental chikungunya vaccine; all 68 patients that were given a single injection of the vaccine showed sustained protection after 12 months. The company is currently running a phase II study and plans to launch a pivotal phase III trial next year. Update […]

November 18, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 15 Nov 2019

UK Spinout Secures Over €3M to Develop Novel Anticoagulants

LUNAC Therapeutics has spun out of the University of Leeds with €3.09M of funding from the university and the VC firm Epidarex Capital for the development of anticoagulants with a lower risk for bleeding than those currently available. The new anticoagulants will target activated factor XII, a protein which company founders Helen Philippou and Richard […]

November 15, 2019 - 2 minutesmins - By External Contributor

News and Trends 14 Nov 2019

Cellectis’ Off-the-Shelf CAR T-Cell Therapy Shows Solid Tumor Potential

An off-the-shelf, gene edited CAR T-cell therapy, developed by the French biotech Cellectis, could be used to tackle solid tumors, which have so far been beyond the reach of other CAR T-cell therapies. The approved CAR T-cell therapies Kymriah and Yescarta contain genetically modified immune T-cells that can fight certain types of blood cancer. However, […]

November 14, 2019 - 2 minutesmins - By Jonathan Smith

bone marrow transplant blood cancer kiadis pharma cell therapy

News and Trends 13 Nov 2019

Mass Layoffs as Dutch Biotech Cancels Phase III Cell Therapy Trial

The Dutch company Kiadis Pharma has discontinued the development of a cell therapy in blood cancer, laid off half of its workforce, and switched focus to other, less advanced cell therapy programs. The abandoned phase III trial was testing Kiadis Pharma’s lead cell therapy for the treatment of graft-versus-host disease, a complication of stem cell […]

November 13, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 12 Nov 2019

First Results Out for Off-the-Shelf CAR-T Therapy in Solid Tumors

The Belgian company Celyad has released the first interim clinical efficacy data for an off-the-shelf CAR T-cell immunotherapy in solid tumors. The interim results come from an ongoing phase I trial in patients with colorectal cancer. Of the 12 patients given Celyad’s CAR T-cell immunotherapy so far, six have seen their tumors shrink. The therapy […]

November 12, 2019 - 2 minutesmins - By Jonathan Smith

Inside Labiotech 12 Nov 2019

Here’s Labiotech.eu’s Master Plan for the Future! 🚀

A few months ago, we introduced Labiotech Insider, our membership program, to our readers. Thanks to your feedback and support, we’re now convinced this model is the way forward for our media. Today marks a new step in our development, with the launch of new features, a new commitment from our investors, and big ambition […]

November 12, 2019 - 6 minutesmins - By Joachim Eeckhout

News and Trends 11 Nov 2019

Argenx Raises Whopping €502M in Global Offering

The Dutch biotech argenx, which develops antibody drugs to treat autoimmune diseases and cancer, has raised an eye-watering €502M ($557M) in a global offering on the Nasdaq Stock Exchange and Euronext Brussels. Argenx’s global offering was launched last week. It consists of a private placement in Europe as well as a public offering in the […]

November 11, 2019 - 2 minutesmins - By Jonathan Smith

mereo biopharma brittle bone disease osteogenesis imperfecta

More News! 11 Nov 2019

Mereo BioPharma’s Brittle Bone Disease Drug Stumbles in Phase II

The lead drug of the UK company Mereo BioPharma has achieved mixed results in a phase IIb trial in adults with the genetic condition osteogenesis imperfecta, also known as brittle bone disease. Mereo tested different doses of its antibody drug in 112 adults with osteogenesis imperfecta in a 12-month phase IIb trial. The drug failed […]

November 11, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 8 Nov 2019

EU Project Receives €15M to Bring mRNA Therapy to a Wider Audience

An EU research project has launched with the aim of bringing mRNA treatments to a wider range of patients and diseases. The EXPERT – Expanding Platforms for Efficacious mRNA Therapeutics – project is a collaboration among academics and industry experts from 11 countries who will work on a novel delivery system for messenger (m)RNA therapeutics […]

November 8, 2019 - 4 minutesmins - By External Contributor

More News! 7 Nov 2019

Avantium Builds 10-Ton Demonstration Plant to Produce Bioplastics

The Dutch bioplastics company Avantium has opened a demonstration plant capable of producing 10 tons per year of mono-ethylene glycol (MEG), a compound used to make plastics, using plants as the starting material. Construction of Avantium’s plant began at Chemie Park Delfzijl, the Netherlands, last year. The plant will extract carbohydrates from agricultural waste and […]

November 7, 2019 - 2 minutesmins - By Jonathan Smith

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

CRISPR Cell Therapy Shows Early Promise for Treating Blood Disorders

US-French Deal to Tailor Ultrasound Therapy to Brain Cancer Patients

Update: Single-Shot Vaccine for Chikungunya Lasts for a Year in Phase I

UK Spinout Secures Over €3M to Develop Novel Anticoagulants

Cellectis’ Off-the-Shelf CAR T-Cell Therapy Shows Solid Tumor Potential

Mass Layoffs as Dutch Biotech Cancels Phase III Cell Therapy Trial

First Results Out for Off-the-Shelf CAR-T Therapy in Solid Tumors

Here’s Labiotech.eu’s Master Plan for the Future! 🚀

Argenx Raises Whopping €502M in Global Offering

Mereo BioPharma’s Brittle Bone Disease Drug Stumbles in Phase II

EU Project Receives €15M to Bring mRNA Therapy to a Wider Audience

Avantium Builds 10-Ton Demonstration Plant to Produce Bioplastics

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!